Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607530 | 0.83 | ERN1 (0.55) | XDHALDH5A1ABATERN1GPR35 | |
| SCHEMBL4301198 | 0.83 | ATM (0.47) | XDHALDH5A1ABATERN1ALDH1A1 | |
| SCHEMBL16838199 | 0.83 | ALDH5A1 (0.55) | XDHALDH5A1ABATERN1GPR35 | |
| SCHEMBL16370945 | 0.81 | ATM (0.48) | XDHALDH5A1ABATERN1ALDH1A1 | |
| SCHEMBL518140 | 0.81 | GPR35 (0.50) | XDHALDH5A1ABATGPR35ALDH1A1 | |
| SCHEMBL2488195 | 0.80 | ERN1 (0.51) | XDHALDH5A1ABATERN1GPR35 | |
| SCHEMBL16838214 | 0.79 | ALDH5A1 (0.55) | XDHALDH5A1ABATERN1GPR35 | |
| SCHEMBL30031583 | 0.79 | TDP1 (0.50) | XDHALDH5A1ABATGPR35ALDH1A1 | |
| SCHEMBL2326899 | 0.79 | TDP1 (0.50) | XDHALDH5A1ABATGPR35ALDH1A1 | |
| SCHEMBL32665668 | 0.79 | XDH (0.50) | XDHALDH5A1ABATERN1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4735048-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-04-30 | — | — | US | disclosed |
| EP-4696691-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Huilun Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025002368-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | BEIGENE, LTD. (GB) | 2025-01-02 | — | — | WO | disclosed |
| CN-117964623-A | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115244053-B | Targeted protein degradation compound and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4238968-A1 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| EP-2852596-A1 | THIENOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2415767-B1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| WO-2013174744-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | XDH 243/4885ALDH5A1 966/4885ABAT 1685/4885 |
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | IRAK4, IRAK1, IRAK2 | XDH 2653/4885ALDH5A1 3606/4885ABAT 3317/4885 |
| US-20260115304-A1 | BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF | GUSB, PSMA6, CD44 | XDH 1733/4885ALDH5A1 3153/4885ABAT 3707/4885 |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | XDH 570/4885ALDH5A1 803/4885ABAT 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.